Search
recombinant factor VIII Fc fusion protein; recombinant antihemophilic factor Fc fusion protein; recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl (Eloctate, Altuviiio)
Indications:
- treatment of hemophilia A
Contraindications:
- hypersensitivity to components
Dosage:
- prophylaxis
- Eloctate
- start: 50 IU/kg every four days
- maintenance: 25 to 65 IU/kg and every three to five days.
- Altuviiioa: weekly [3]
General
coagulation factor VIII; antihemophilic factor; AHF; procoagulant component; contains: factor VIIIa heavy chain, 200 kD & 92 isoforms; factor VIII B chain; factor VIIIa light chain (F8, F8C)
recombinant protein; chimer
fusion protein
References
- FDA News Release. June 6, 2014
FDA approves the first antihemophilic factor, Fc fusion protein
for patients with Hemophilia A.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm400167.htm
- biogen idec. Press Release. June 6, 2014
FDA Approves Biogen Idec's s ELOCTATE, First Hemophilia A
Therapy to Extend the Interval between Prophylactic Infusions,
for Both Adults and Children.
http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2338&M=NewsV2&PID=61997
- Bassett M
FDA Approves Weekly Factor Therapy for Hemophilia A.
Factor VIII replacement therapy provides protection from bleeds with once-weekly
dosing.
MedPage Today February 23, 2023
https://www.medpagetoday.com/hematologyoncology/hemophilia/103246